The patient claimed her vital signs had indicated internal bleeding within 2 hours after delivery, but an exploratory laparotomy was not performed for almost 5 hours. Read the facts, and see what you think.
For details on the lawsuit, click "Next."
Tebipenem HBr cUTI trial ends early after meeting efficacy goals
May 28th 2025GSK and Spero Therapeutics announced that the phase 3 PIVOT-PO trial for tebipenem HBr, a potential first oral carbapenem for cUTIs in the United States, was stopped early because of positive efficacy results.
Read More